Turkey may be Europe's sixth largest pharmaceutical industry, but it's looking to ascend the ranks with a boost from GE Healthcare. The company is launching a collaborative research scheme to support Turkey's bioprocessing development and manufacturing.
Tokyo-based Chugai Pharmaceutical and research partner PharmaMar have announced that their investigational new multiple myeloma drug that has been developed from a marine animal significantly increased survival in certain patients.
There was a lot of back slapping at this year's Australian Clinical Trial Seminar as trade group AusBiotech spoke of its desire to work more closely with Korea's growing life science industry.
The inland city of Chengdu in China's Sichuan province is betting big on biotech, announcing a plan last month for an RMB2 billion ($306 million) fund to attract startups, raising some observations on how the policy might play out in competition with other centers in China and nearby in Asia.
India's Dr. Reddy's Laboratories has snapped up a chunk of development rights for Tokyo-based Eisai's Phase II oncology candidate E7777 in Japan that aimed at skin T-cell lymphoma and with plans afoot for a U.S. Phase III trial.
Months after splurging on a new headquarters, Berkeley, CA-based Aduro Biotech is tightening its ties to the city, dropping $7.5 million on a new collaboration with the University of California, Berkeley. The three-year Immunotherapeutics and Vaccine Research Initiative will target cancers and other diseases, the duo announced in a statement on Monday.
Biopharma companies that have struggled to make a splash in the U.S. or European markets with their new treatments are increasingly turning to China for a reprieve.
Sanofi Pasteur and the University of Georgia this week talked up details of a next-gen flu vaccine strategy that the pair hopes can build on the strength of current vaccines but broaden protection to avoid the problems associated with strain drift.
Snapdragon Chemistry is expanding its team, working space, and corporate partnership and has elected a new CEO in a major update from the privately held CRO.
Japan has approved a new biosimilar of Sanofi's blockbuster Lantus (insulin glargine) as its creator Biocon chalks up a much-needed win after a tough 2015.